Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the benefits of investigational drug, NRX 194204 in slowing
down/stopping/reversing progression of the castration resistant and taxane resistant prostate
cancer.